CoChat
Sign Up
Cited by 110Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementImmunotherapy and Immune Responses

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

Open access
Morales, Rita E, Shoushtari, Alexander N, Walsh, Michelle M, Grewal, Priya, Lipson, Evan J, Carvajal, Richard D·2015·Journal for ImmunoTherapy of Cancer
DOI 10.1186/s40425-015-0066-0PMC PMC4469313
Open this paper in CoChat — free accountOpen PDF

Abstract

Ipilimumab is a first-in-class immunological checkpoint blockade agent and monoclonal antibody against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) that has demonstrated survival benefit and durable responses in patients with metastatic melanoma. To date, solid organ transplant recipients have been excluded from clinical trials with cancer immunotherapies on the basis of their concurrent treatment with immunosuppressive agents. We present the first case to our knowledge of a patient with advanced cutaneous melanoma receiving ipilimumab status post orthotopic liver transplantation with a partial response. Transaminitis was observed 4 months after administration of ipilimumab that resolved with close observation. No evidence of graft rejection has been observed to date. This case advocates for further investigation of the safety and efficacy of cancer immunotherapies in solid organ transplant recipients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-015-0066-0

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Demonstration of changes in AST/ALT values over time with administration of ipilimumab; AST and ALT levels were measured weekly during the administration of ipilimumab. Sixteen weeks following initial induction, AST and ALT levels peaked at Grade 3. Resolution to Grade 1 was seen at Week 20, and monthly monitoring of liver function tests has been performed since, with continued evidence of stability. Arrows denote the times of administration of ipilimumab.
Figure 1 Demonstration of changes in AST/ALT values over time with administration of ipilimumab; AST and ALT levels were measured weekly during the administration of ipilimumab. Sixteen weeks following initial induction, AST and ALT levels peaked at Grade 3. Resolution to Grade 1 was seen at Week 20, and monthly monitoring of liver function tests has been performed since, with continued evidence of stability. Arrows denote the times of administration of ipilimumab.CC BY · PubMed Central
Figure 2 Demonstration of radiographic response to ipilimumab; CT scans performed prior to and 12 weeks after initiation of therapy demonstrate regression of lung and liver metastases (arrows).
Figure 2 Demonstration of radiographic response to ipilimumab; CT scans performed prior to and 12 weeks after initiation of therapy demonstrate regression of lung and liver metastases (arrows).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

Sorted by citations

Items 101–110 of 110

Related

See all

Metadata

Authors
Morales, R. E., Shoushtari, A. N., Walsh, M. M., Grewal, P., Lipson, E. J., & Carvajal, R. D.
Affiliations
  • Columbia University (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Columbia University Irving Medical Center (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Johns Hopkins University (US)
Corresponding author
Carvajal, Richard D
ORCID
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2015-06-16
Volume
3
Issue
1
Pages
22-22
ISSN
2051-1426 (ISSN-L)
DOI
10.1186/s40425-015-0066-0
PMC
PMC4469313
OpenAlex
W1517732299
Cited by
110
References
12
Citations by year
2026: 1 · 2025: 1 · 2024: 6 · 2023: 9 · 2022: 11 · 2021: 12 · 2020: 10 · 2019: 9 · 2018: 13 · 2017: 21 · 2016: 13 · 2015: 2
FWCI
7.13
Type
journal article
Language
en
Open access
Licence
creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Columbia Academic Commons (Columbia University)
Funders
National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
ipilimumab, liver transplantation, CTLA-4 blockade, cancer immunotherapy, solid organ transplant recipients, elevated liver enzymes, graft rejection, immunosuppression, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review